Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dupixent FDA Asthma Review Bolsters Sanofi And Regeneron

Executive Summary

Already approved for atopic dermatitis, the partners have got a PDUFA date of Oct. 20 which could expand the label on their interleukin-4 and -13 inhibitor to include asthma.

Advertisement

Related Content

Severe Asthma Market Snapshot: A Competitive Therapy Area That Will Test Payers' Influence
Dupixent Shines At ATS, But Experts Question Which Novel Biologic Physicians Will Choose
Dupixent Hits Endpoints In Adolescents, Filing Expected In Q3
Regeneron Tries To Put Focus On PD-1 Program, Not Sluggish Autoimmune Sales
Keeping Track: Delay (For Celgene), Delay (For Allergan), Goose! (Approval For Lilly)
AAD Roundup: More Data Emerges In Atopic Dermatitis, But Dupixent Maintains Big Lead
Sanofi Starts 2018 As It Means To Go On: More Transactions Expected

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100496

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel